GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Cyclically Adjusted PS Ratio

Benitec Biopharma (ASX:BLT) Cyclically Adjusted PS Ratio : (As of Jun. 14, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Benitec Biopharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Benitec Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Cyclically Adjusted PS Ratio Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Benitec Biopharma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted PS Ratio falls into.



Benitec Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Benitec Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Benitec Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Benitec Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.004 100.684 0.005
201509 0.002 100.392 0.003
201512 0.001 99.792 0.001
201603 0.001 100.470 0.001
201606 0.000 101.688 0.000
201609 0.001 101.861 0.001
201612 0.001 101.863 0.001
201703 0.001 102.862 0.001
201706 -0.001 103.349 -0.001
201709 0.001 104.136 0.001
201712 0.001 104.011 0.001
201803 0.001 105.290 0.001
201806 -0.001 106.317 -0.001
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Benitec Biopharma  (ASX:BLT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Benitec Biopharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009